{"id":"antihyperglycemic-agent-s","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a broad drug class category rather than a single agent. Antihyperglycemic agents encompass multiple drug classes (e.g., metformin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors, DPP-4 inhibitors) that lower blood glucose through distinct mechanisms. Without specification of the exact agent or mechanism from Janssen's Phase 3 program, the precise molecular target and mechanism cannot be determined.","oneSentence":"Antihyperglycemic agents work by reducing blood glucose levels through various mechanisms such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:04.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT06906172","phase":"NA","title":"The REmission of Diabetes Using a PlAnt-based Weight Loss InteRvention (REPAIR) Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Toronto","startDate":"2025-09","conditions":"Diabetes Mellitus","enrollment":160},{"nctId":"NCT00327626","phase":"PHASE2","title":"Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea","status":"WITHDRAWN","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2006-05-01","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT03798080","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-19","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03798054","phase":"PHASE3","title":"Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-15","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT01499095","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":811},{"nctId":"NCT03713684","phase":"PHASE3","title":"Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-11-09","conditions":"Type 2 Diabetes Mellitus","enrollment":370},{"nctId":"NCT03687827","phase":"PHASE4","title":"A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":498},{"nctId":"NCT04521049","phase":"PHASE4","title":"Tubular Markers in Response to Saxagliptin Therapy","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT00603291","phase":"PHASE3","title":"BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-12","conditions":"Obesity","enrollment":604},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT02738151","phase":"PHASE4","title":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-19","conditions":"Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT02131272","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2014-06-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT01790438","phase":"PHASE3","title":"A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Diabetes Mellitus, Type 2","enrollment":641},{"nctId":"NCT02660047","phase":"PHASE4","title":"Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2015-08","conditions":"Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease","enrollment":51},{"nctId":"NCT01034111","phase":"PHASE3","title":"A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-03-01","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT00104182","phase":"PHASE3","title":"Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":503},{"nctId":"NCT02585674","phase":"PHASE3","title":"Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":151},{"nctId":"NCT01761318","phase":"PHASE4","title":"Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2013-11","conditions":"Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease","enrollment":50},{"nctId":"NCT01676220","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT00907881","phase":"","title":"The OBSTACLE Hypoglycemia Study (MK-0000-158)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":1069},{"nctId":"NCT01106651","phase":"PHASE3","title":"A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":716},{"nctId":"NCT01689142","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT00949442","phase":"PHASE4","title":"Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00551538","phase":"PHASE4","title":"24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-05","conditions":"Type 2 Diabetes","enrollment":15},{"nctId":"NCT00139659","phase":"PHASE3","title":"A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Asthma, Diabetes Mellitus","enrollment":288},{"nctId":"NCT00138671","phase":"PHASE3","title":"A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Diabetes Mellitus, Chronic Obstructive Pulmonary Disease","enrollment":105},{"nctId":"NCT00405418","phase":"PHASE4","title":"Lantus Versus Levemir Treat-To-Target","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-11","conditions":"Diabetes Mellitus, Type 2","enrollment":973},{"nctId":"NCT00653341","phase":"PHASE3","title":"Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2000-01","conditions":"Diabetes Mellitus, Type 2","enrollment":764}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Antihyperglycemic agent(s)","genericName":"Antihyperglycemic agent(s)","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antihyperglycemic agents include insulin detemir and insulin NPH, which are used to treat conditions such as type 2 diabetes mellitus. These medications are typically used in conjunction with diet and exercise as part of a comprehensive treatment plan.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}